NCT05277012View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Healthy Participants
Interventions
DRUG

Etrumadenant

Etrumadenant capsule and tablet formulations

Trial Locations (1)

68502

Investigational Site, Lincoln

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Arcus Biosciences, Inc.

INDUSTRY

NCT05277012 - A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants | Biotech Hunter | Biotech Hunter